Our pipeline is feeding cures and treatments.
a pipeline for a cure
Genvoyn is building a next-generation oncology platform with one mission: to stop cancer in its tracks. Our lead program, Tripsovyn, is targeting Triple-Negative Breast Cancer (TNBC)—one of the most aggressive and hardest-to-treat forms of cancer, where current therapies fall short. Unlike traditional treatments that depend on hormone or HER2 receptor pathways, Tripsovyn is designed to work independently of these mechanisms, opening a powerful new front in cancer therapy. With three novel small molecules and four unique drug combinations in preclinical development, the scientific foundation is strong and differentiated.
We are also developing a companion diagnostic (CDx) to ensure that each patient receives the right treatment for their unique biology. This precision-driven model not only improves patient outcomes but also strengthens market adoption by reducing trial-and-error in cancer care. By leveraging AI to accelerate discovery and optimize treatment pathways, Genvoyn stands at the intersection of biotechnology and technology—a space where innovation is redefining healthcare. For investors, this means the potential to back a first-in-class therapy, a scalable platform, and a pipeline designed to reshape oncology.
pipeline status
Our business strategy focuses on completing the preclinical development of each asset and advancing it through Phase 1 of clinical trials. Once we have successful candidates, we plan to gradually sell them to a pharmaceutical company partner that can fund and complete the clinical trials, as well as manufacture and distribute these powerful new drugs. Additionally, we will collaborate with a laboratory to develop companion diagnostics (CDx) for these therapeutics.
TNBC Novel Molecules
Pancreatic Cancer – New Targets
Immuno-Oncology New Targets
The Genovyn Difference
Genovyn’s model fuses the agility of a biotech incubator with the rigor of a global CRO. By aligning our deep discovery science from Genovyn’s clinical and commercial leadership, we deliver a scalable, efficient path from innovation to market — accelerating therapies that improve patient outcomes and investor returns alike.
